• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA501-5p 通过激活 mTOR/MDM2 通路诱导 ADPKD 细胞中 p53 的蛋白酶体降解。

MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.

机构信息

Department of Biomedical and Surgical Specialty Sciences, University of Ferrara, Ferrara, Italy.

Unit of Urology, St. Anna Hospital, Ferrara, Italy.

出版信息

J Cell Physiol. 2018 Sep;233(9):6911-6924. doi: 10.1002/jcp.26473. Epub 2018 Mar 25.

DOI:10.1002/jcp.26473
PMID:29323708
Abstract

Cell proliferation and apoptosis are typical hallmarks of autosomal dominant polycystic kidney disease (ADPKD) and cause the development of kidney cysts that lead to end-stage renal disease (ESRD). Many factors, impaired by polycystin complex loss of function, may promote these biological processes, including cAMP, mTOR, and EGFR signaling pathways. In addition, microRNAs (miRs) may also regulate the ADPKD related signaling network and their dysregulation contributes to disease progression. However, the role of miRs in ADPKD pathogenesis has not been fully understood, but also the function of p53 is quite obscure, especially its regulatory contribution on cell proliferation and apoptosis. Here, we describe for the first time that miR501-5p, upregulated in ADPKD cells and tissues, induces the activation of mTOR kinase by PTEN and TSC1 gene repression. The increased activity of mTOR kinase enhances the expression of E3 ubiquitin ligase MDM2 that in turn promotes p53 ubiquitination, leading to its degradation by proteasome machinery in a network involving p70S6K. Moreover, the overexpression of miR501-5p stimulates cell proliferation in kidney cells by the inhibition of p53 function in a mechanism driven by mTOR signaling. In fact, the downregulation of this miR as well as the pharmacological treatment with proteasome and mTOR inhibitors in ADPKD cells reduces cell growth by the activation of apoptosis. Consequently, the stimulation of cell death in ADPKD cells may occur through the inhibition of mTOR/MDM2 signaling and the restoring of p53 function. The data presented here confirm that the impaired mTOR signaling plays an important role in ADPKD.

摘要

细胞增殖和凋亡是常染色体显性多囊肾病(ADPKD)的典型标志,导致肾囊肿的发展,进而导致终末期肾病(ESRD)。许多因素,包括 cAMP、mTOR 和 EGFR 信号通路,可能会因多囊蛋白复合物功能丧失而受到损害,从而促进这些生物过程。此外,microRNAs(miRs)也可能调节 ADPKD 相关信号网络,其失调导致疾病进展。然而,miRs 在 ADPKD 发病机制中的作用尚未完全阐明,p53 的功能也相当模糊,尤其是其对细胞增殖和凋亡的调节作用。在这里,我们首次描述了 miR501-5p 在 ADPKD 细胞和组织中上调,通过 PTEN 和 TSC1 基因抑制诱导 mTOR 激酶的激活。mTOR 激酶活性的增加增强了 E3 泛素连接酶 MDM2 的表达,进而促进 p53 的泛素化,导致其在一个涉及 p70S6K 的网络中被蛋白酶体机制降解。此外,miR501-5p 的过表达通过抑制 mTOR 信号驱动的 p53 功能,刺激肾脏细胞的增殖。事实上,通过下调这种 miR 以及在 ADPKD 细胞中用蛋白酶体和 mTOR 抑制剂进行药理学治疗,可以通过激活细胞凋亡来减少细胞生长。因此,通过抑制 mTOR/MDM2 信号和恢复 p53 功能,可能会在 ADPKD 细胞中刺激细胞死亡。本文提供的证据证实,受损的 mTOR 信号在 ADPKD 中发挥重要作用。

相似文献

1
MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.微小 RNA501-5p 通过激活 mTOR/MDM2 通路诱导 ADPKD 细胞中 p53 的蛋白酶体降解。
J Cell Physiol. 2018 Sep;233(9):6911-6924. doi: 10.1002/jcp.26473. Epub 2018 Mar 25.
2
Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.对环磷酸腺苷(cAMP)和雷帕霉素靶蛋白(mTOR)信号通路的双重抑制可能会增强常染色体显性多囊肾病(ADPKD)细胞中细胞生长的减少。
Clin Exp Nephrol. 2017 Apr;21(2):203-211. doi: 10.1007/s10157-016-1289-1. Epub 2016 Jun 9.
3
MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.微小RNA-15/16复合体靶向p70核糖体蛋白S6激酶1并调控MDA-MB-231乳腺癌细胞的增殖。
Gene. 2014 Dec 1;552(2):255-64. doi: 10.1016/j.gene.2014.09.052. Epub 2014 Sep 26.
4
The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.MDM2的抑制作用减缓了常染色体显性多囊肾病(ADPKD)细胞系中的细胞增殖并激活了细胞凋亡。
Biol Cell. 2023 Jan;115(1):e2200037. doi: 10.1111/boc.202200037. Epub 2022 Oct 10.
5
Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.miR-501-5p 的差异表达影响透明细胞肾细胞癌的侵袭性。
FEBS Open Bio. 2014 Nov 4;4:952-65. doi: 10.1016/j.fob.2014.10.016. eCollection 2014.
6
Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.小檗碱可减缓常染色体显性多囊肾病细胞的生长。
Biochem Biophys Res Commun. 2013 Nov 22;441(3):668-74. doi: 10.1016/j.bbrc.2013.10.076. Epub 2013 Oct 31.
7
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).用西罗莫司抑制哺乳动物雷帕霉素靶蛋白(mTOR)可减缓常染色体显性遗传性多囊肾病(ADPKD)的Han:SPRD大鼠的疾病进展。
Nephrol Dial Transplant. 2006 Mar;21(3):598-604. doi: 10.1093/ndt/gfi181. Epub 2005 Oct 12.
8
Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.p53和HIF1α在人肾癌细胞凋亡中对mTOR和MDM2信号通路抑制的协同作用。
Drug Des Devel Ther. 2016 Feb 18;10:745-55. doi: 10.2147/DDDT.S88779. eCollection 2016.
9
Multidrug therapy for polycystic kidney disease: a review and perspective.多囊肾病的多药治疗:综述与展望。
Am J Nephrol. 2013;37(2):175-82. doi: 10.1159/000346812. Epub 2013 Feb 15.
10
MDM2 mediates fibroblast activation and renal tubulointerstitial fibrosis via a p53-independent pathway.MDM2 通过一条不依赖 p53 的途径介导成纤维细胞活化和肾间质纤维化。
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F760-F768. doi: 10.1152/ajprenal.00528.2016. Epub 2017 Jan 18.

引用本文的文献

1
Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?尿液生物标志物在监测常染色体显性遗传性多囊肾病的进展和治疗中的应用——是否充满希望?
Medicina (Kaunas). 2023 May 10;59(5):915. doi: 10.3390/medicina59050915.
2
Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease.非编码RNA作为多囊肾病的潜在生物标志物和治疗靶点
Front Physiol. 2022 Sep 20;13:1006427. doi: 10.3389/fphys.2022.1006427. eCollection 2022.
3
Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.
多囊肾病表观遗传修饰的最新发现。
Int J Mol Sci. 2021 Dec 11;22(24):13327. doi: 10.3390/ijms222413327.
4
NS398 as a potential drug for autosomal-dominant polycystic kidney disease: Analysis using bioinformatics, and zebrafish and mouse models.NS398 作为一种治疗常染色体显性遗传多囊肾病的潜在药物:生物信息学分析及斑马鱼和小鼠模型研究。
J Cell Mol Med. 2021 Oct;25(20):9597-9608. doi: 10.1111/jcmm.16903. Epub 2021 Sep 22.
5
Non-Coding RNAs in Hereditary Kidney Disorders.非编码 RNA 在遗传性肾脏疾病中的作用。
Int J Mol Sci. 2021 Mar 16;22(6):3014. doi: 10.3390/ijms22063014.
6
MicroRNAs and Polycystic Kidney Disease.微小RNA与多囊肾病
Kidney Med. 2020 Sep 21;2(6):762-770. doi: 10.1016/j.xkme.2020.06.013. eCollection 2020 Nov-Dec.
7
Perivascular epithelioid cell tumor (PEComa) of the kidney: an overview of its management and outcomes.肾血管周上皮样细胞瘤(PEComa):管理和结局概述。
J Int Med Res. 2020 Oct;48(10):300060520961223. doi: 10.1177/0300060520961223.
8
miR-25-3p promotes proliferation and inhibits autophagy of renal cells in polycystic kidney mice by regulating ATG14-Beclin 1.微小RNA-25-3p通过调控自噬相关蛋白14(ATG14)-自噬相关蛋白1(Beclin 1)促进多囊肾小鼠肾细胞增殖并抑制其自噬。
Ren Fail. 2020 Nov;42(1):333-342. doi: 10.1080/0886022X.2020.1745236.
9
Degradation of proteins by PROTACs and other strategies.通过PROTACs和其他策略进行蛋白质降解
Acta Pharm Sin B. 2020 Feb;10(2):207-238. doi: 10.1016/j.apsb.2019.08.001. Epub 2019 Aug 13.
10
Identification of housekeeping genes for microRNA expression analysis in kidney tissues of Pkd1 deficient mouse models.鉴定微小 RNA 表达分析在 Pkd1 缺陷型小鼠模型肾脏组织中的管家基因。
Sci Rep. 2020 Jan 14;10(1):231. doi: 10.1038/s41598-019-57112-4.